#Czech Republic #AIxMed #Biopticka #Cytology #Plzeň

AIxMed and Biopticka Laboratoř Form Strategic Alliance

In a groundbreaking development in the field of medical diagnostics, AIxMed Inc., a notable innovator in computational cytology, has joined forces with Biopticka Laboratoř s.r.o., a leading reference laboratory based in the Czech Republic. Their recent Memorandum of Understanding (MOU) aims to implement AIxURO™, an advanced AI-powered solution specifically developed for urine cytology. This collaboration marks a significant step towards enhancing the diagnostic accuracy and efficiency in detecting bladder cancer across Europe.

Establishing a Flagship Laboratory for AI-Driven Cytology

Under the terms of the MOU, Biopticka Laboratoř will serve as a pioneer reference site for AIxMed in Europe, showcasing the practical applications of AIxURO™ to prospective partners and clients. This partnership, bolstered by AIxMed's collaborations with leading whole-slide imaging providers, aims to further Biopticka's emergence as a flagship AI-focused cytology laboratory in the region. The integration of AIxURO™ into Biopticka's Laboratory Information System (LIS) is set to streamline existing workflows within their digital pathology infrastructure.

Broadening the Horizons of Cytology

While the initial focus of this collaboration is the detection of bladder cancer, both parties have expressed intentions to delve deeper into various high-impact cytology applications. There are plans to pursue joint research collaborations, clinical validation studies, and the co-authoring of publications to propel the integration of AI technology within the cytology domain.

Visionary Statements from Executives

Samuel Chen, the CEO and Co-founder of AIxMed, shared his enthusiasm about the partnership, stating, “Our mission is to transform cancer diagnosis through computational cytology, and this partnership with Biopticka is a significant step towards that vision. Together, we will accelerate the adoption of advanced AI tools that improve diagnostic accuracy, efficiency, and ultimately patient outcomes.”

On the other hand, Michael Michal, the statutory executive of Biopticka, emphasized their commitment to incorporating cutting-edge diagnostic technologies into clinical practice. He remarked, “By adopting AIxMed's AIxURO™ and collaborating on future innovations, we will enhance our services and deliver meaningful improvements in care for patients across the region.”

About AIxMed Inc.

Established in 2018 and headquartered in Santa Clara, California, AIxMed Inc. has emerged as a frontrunner in pioneering computational cytology aimed at revolutionizing cancer diagnosis and monitoring. Their flagship solution, AIxURO™, leverages artificial intelligence and The Paris System to assist in bladder cancer detection, ultimately fostering improved accuracy and workflow efficiency. Currently, AIxURO™ is designated for research use only, reflecting the company's ongoing commitment to innovation.

About Biopticka Laboratoř s.r.o.

Biopticka Laboratoř, situated in Plzeň, Czech Republic, is a reputable reference laboratory that specializes in pathology, histology, and molecular genetics. Renowned for delivering precise and timely diagnostics, Biopticka collaborates closely with hospitals and clinicians across Central and Eastern Europe to offer high-quality, patient-centered diagnostic services.

This partnership between AIxMed and Biopticka Laboratoř signifies not only a pivotal collaboration aimed at improving healthcare outcomes but also highlights the growing role of artificial intelligence in the medical field, particularly in enhancing the capabilities and reliability of diagnostic processes. As both companies move forward, they underline their dedication to employing the latest innovations to benefit patients and medical professionals alike.